Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 268 | 268 | 95 |
Full Text Views | 20 | 20 | 10 |
PDF Downloads | 31 | 31 | 16 |
Anemia is common among people living with HIV (PLWH), particularly in Africa. Outcomes for PLWH on modern antiretroviral therapy (ART) regimens are not well documented. We conducted an observational study to determine the outcomes and predictors of anemia after ART initiation in Tanzania. We enrolled and followed ART-naïve PLWH and HIV-uninfected individuals at three clinics in Tanzania. We grouped participants into four longitudinal categories based on hemoglobin concentration measured at baseline and 6 months after ART initiation (normal, resolved anemia, incident anemia, and persistent anemia) and followed them for 24 months. There were 991 study participants (494 PLWH, 497 HIV uninfected). After 6 months of ART, 33.9% of PLWH had persistent anemia and 9.9% had incident anemia compared with 12.6% and 9.6% for HIV-uninfected controls. Female sex (adjusted odds ratio [aOR]: 2.62; 95% CI: 1.91–6.75) and low income (aOR: 3.10; 95% CI: 1.36–7.20) were strong predictors of persistent anemia for both PLWH and HIV-uninfected individuals. For PLWH, having a CD4+ T cell count of less than 350 cells/mm3 (aOR: 0.34; 95% Cl: 0.15–0.73) was significantly associated with anemia resolution. Mortality was higher for PLWH who had persistent anemia or incident anemia than for PLWH who had normal hemoglobin or improved anemia (hazard ratio: 4.0, 95% Cl 1.3–12.2). One-third of adults in Tanzania had persistent anemia after 6 months on ART, and persistent anemia was associated with increased mortality. PLWH with persistent or incident anemia after 6 months on modern ART deserve close follow-up, particularly women and low-income adults.
Financial support: This study was supported by R. N. Peck’s
Disclosures: This study protocol was reviewed and approved by the institutional review boards of Weill Cornell Medicine (1506016328), the Tanzanian National Institute of Medical Research (NIMR/HQ/R.8c/Vol.1/1399), and Bugando Medical Center (CREC/074/2015). All study procedures were performed in accordance with the World Medical Association Declaration of Helsinki. All participants provided written informed consent.
Current contact information: Duncan K. Hau, Department of Pediatrics, Weill Cornell Medical College, New York, NY, E-mail: dkh2001@med.cornell.edu. Salama Fadhil, Mwanza Intervention Trials Unit, Mwanza, Tanzania, E-mail: salama.fadhil@mitu.or.tz. Myung Hee Lee, Megan Willkens, and Robert N. Peck, Center for Global Health, Weill Cornell Medical College, New York, NY, E-mails: myl2003@med.cornell.edu, maw4016@med.cornell.edu, and rnp2002@med.cornell.edu. Bernard Desderius and Samuel E. Kalluvya, Department of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania, E-mails: bm.desderius@gmail.com and samuelkalluvya@yahoo.com. Erius Tebuka, Department of Pathology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania, E-mail: eriust@yahoo.com. Luke R. Smart, Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, E-mail: luke.smart@cchmc.org.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 268 | 268 | 95 |
Full Text Views | 20 | 20 | 10 |
PDF Downloads | 31 | 31 | 16 |